Skip to main content
. 2020 Sep 11;42(6):998–1004. doi: 10.1038/s41401-020-00513-3

Fig. 1. SAF-189s is highly potent against ROS1 wild-type and G2032R mutant kinases.

Fig. 1

Kinase activity inhibition curve of SAF-189s against ROS1 (a), ROS1G2032R (b), and ROS1L2026M (c). d IC50 values of SAF-189s, lorlatinib, ceritinib, and crizotinib against the kinase activity of ROS1 and a series of crizotinib-resistant mutants. e SAF-189s functions in an ATP-competitive manner to inhibit ROS1 kinases. The values shown in Fig.1 represent the mean ± SD.